Phase 4 Breast Cancer Trial, Recruiting NCT04136782 Sponsor: Shengjing Hospital Condition: Breast Cancer
Back to Breast Cancer

Phase 4 Breast Cancer Trial, Recruiting

NCT04136782
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with breast cancer confirmed by imaging, and your cancer tests negative for estrogen receptor, progesterone receptor, and HER2 (sometimes called "triple-negative" breast cancer) at stage II or III
  • Doctors estimate you are likely to live more than 3 months
  • You have at least one area of cancer that can be measured by scans or physical exam
  • You are generally able to carry out normal daily activities (assessed using a standard health score of 70 or above on a doctor's scale)
  • Your blood tests, liver and kidney function, and heart reading (ECG) are within normal or near-normal ranges
  • You are between 18 and 70 years old

Who may not be able to join:

  • Your breast cancer has spread to the bones or other distant parts of the body (stage IV)
  • You have serious kidney problems
  • You are an older adult with serious heart or lung disease, and your doctor does not think you could handle chemotherapy
  • You have already received cancer treatment
  • You started a pre-surgery chemotherapy plan but it did not work after 2 rounds and you switched to a different treatment or stopped chemotherapy
  • You have a history of any other type of cancer
  • You have serious heart, liver, or kidney problems, or poor overall health that means you cannot tolerate chemotherapy, or you have already switched to a different type of treatment
  • You have a mental health or neurological condition that would make it difficult to follow the treatment plan
  • You have an intolerance to the steroid medication dexamethasone, or a strong allergy to any of the chemotherapy drugs used in this trial
  • You are currently pregnant or breastfeeding
  • You are already taking part in another clinical trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Caigang Liu, M.D., Ph.D., Shengjing Hospital

Phone: +86 18940255116

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Shengjing Hospital
Registry
ClinicalTrials.gov
Start date
19 July 2021
Est. completion
30 November 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Pathologic complete remission rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov